Condition: Triple Negative Breast Cancer · Sponsor: Gilead Sciences
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
This description comes directly from the study's public registry record.
Gilead Clinical Study Information Center · 1-833-445-3230 (GILEAD-0) · GileadClinicalTrials@gilead.com
Always discuss trial participation with your own doctor first.
| Alabama Oncology | Birmingham, Alabama, United States | Recruiting |
| Clearview Cancer Institute | Huntsville, Alabama, United States | Recruiting |
| Palo Verde Hematology Oncology | Glendale, Arizona, United States | Recruiting |
| Mayo Clinic Hospital | Phoenix, Arizona, United States | Withdrawn |
| Arizona Oncology Associates | Prescott Valley, Arizona, United States | Withdrawn |
| Alta Bates Summit Medical Center | Berkeley, California, United States | Recruiting |
| Community Cancer Institute | Clovis, California, United States | Withdrawn |
| PIH Health Whittier Hospital | Downey, California, United States | Recruiting |
| Compassionate Cancer Care Medical Group - Inc | Fountain Valley, California, United States | Recruiting |
| Los Angeles Cancer Network | Los Angeles, California, United States | Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Withdrawn |
| Cedars-Sinai Cancer at Beverly Hills | Los Angeles, California, United States | Recruiting |
+ 344 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05633654